12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga_article·Oct 1, 2026 at 09:06 PMAGMB-1.04%AZTR+2.72%
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trialbenzinga_article·Oct 1, 2026 at 06:31 PMAGMB-1.04%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Oct 1, 2026 at 05:06 PMAGMB-1.04%ATHA0.00%
AGMB: Ontunisertib showed sustained safety and disease control in FSCD, supporting Phase 2b initiationQuartr·Oct 1, 2026 at 10:33 AMAGMB-1.04%
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease | AGMB Stock NewsStockTitan·Oct 1, 2026 at 02:30 AMAGMB-1.04%
Agomab Therapeutics director Naimish Patel files initial beneficial ownership statementPUBT·Sep 15, 2026 at 08:06 PMAGMB-1.04%
Agomab Moves Inhaled IPF Drug AGMB-447 Into Phase 2 After Positive Phase 1 ResultsTip Ranks·Sep 14, 2026 at 08:38 PMAGMB-1.04%
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors | AGMB Stock NewsStockTitan·Sep 11, 2026 at 12:05 PMAGMB-1.04%
